Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals (XENE) is a clinical-stage biopharmaceutical company pioneering neuroscience therapies through its innovative extreme genetics platform. This page serves as the definitive source for verified company news, providing investors and researchers with timely updates on therapeutic advancements and strategic developments.
Access curated press releases covering clinical trial milestones, regulatory updates, and research collaborations. Our news collection focuses on XENE's work identifying novel drug targets through genetic analysis of severe disorders, particularly in neurology and psychiatry. Track progress across their pipeline of precision therapies targeting ion channels and neurological pathways.
Key updates include phase trial results, patent filings, executive appointments, and scientific presentations. All content is vetted for accuracy and relevance to investment research. Bookmark this page for efficient monitoring of XENE's progress in genetic-driven drug discovery and partnership announcements within the neuroscience sector.
Xenon Pharmaceuticals, focused on neurology, announced its participation in key investor conferences. The Jefferies Biotech on the Bay Summit is scheduled for April 26-27, 2022, in Miami, FL, featuring one-on-one meetings. The Bloom Burton & Co. Healthcare Investor Conference will take place on May 2-3, 2022, in Toronto, with a presentation on May 3 at 11:30 am ET. Lastly, the RBC Capital Markets Global Healthcare Conference will occur on May 17-18, 2022, in New York, highlighted by a fireside chat on May 18 at 11:00 am ET. For further details, visit Xenon's investor page.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has announced participation in one-on-one investor meetings and a fireside chat at the 21st Annual Needham (Virtual) Healthcare Conference on April 11, 2022. The fireside chat will occur from 10:15-10:55 am Eastern Time, featuring Ian Mortimer, President and CEO, and Sherry Aulin, CFO. Recordings of the presentation will be available post-event on their website. The company is dedicated to developing innovative therapies for neurological disorders, particularly focusing on epilepsy.
Xenon Pharmaceuticals (Nasdaq:XENE) announced participation in the Stifel 2022 CNS Days virtual conference on March 29, 2022. Management will engage in one-on-one investor meetings and a fireside chat from 11:00-11:25 am Eastern Time. Presenters include Ian Mortimer, President and CEO, and Chris Von Seggern, Chief Commercial Officer.
The company focuses on developing innovative therapeutics for neurological disorders and has a pipeline aimed at addressing high unmet medical needs, particularly in epilepsy.
Xenon Pharmaceuticals (Nasdaq:XENE) reported its 2021 financial results, highlighting significant advancements in clinical trials, particularly for XEN1101, a treatment for epilepsy and major depressive disorder. The Phase 2b X-TOLE trial showed strong efficacy, prompting plans for a Phase 3 development in 2022. Financially, total revenue dropped to $18.4 million with a net loss of $78.9 million, attributed to increased R&D and administrative expenses. Xenon maintains a robust cash position of $551.8 million, sufficient to fund operations into at least 2024.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will release its financial results for the year ended December 31, 2021, on March 1, 2022. This announcement follows the closing of U.S. financial markets. A conference call and live audio webcast will take place on the same day at 4:30 PM Eastern Time to discuss these results and provide a corporate update. The company focuses on developing therapies for neurological disorders, particularly epilepsy. Investors can access more details on their website for further updates and replay options.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022. The company will conduct one-on-one investor meetings and a virtual fireside chat.
The chat is scheduled for 5:00-5:30 pm ET and will be presented by Ian Mortimer, the President and CEO. Attendees can access details and webcasts on the company’s website after the event.
Xenon is focused on developing innovative treatments for neurological disorders, particularly epilepsy.
Xenon Pharmaceuticals (Nasdaq:XENE) announced a significant regulatory milestone in its collaboration with Neurocrine Biosciences (Nasdaq:NBIX), resulting in a $15 million aggregate payment to Xenon. The FDA has accepted a protocol amendment that permits inclusion of pediatric patients aged 2-11 in the Phase 2 study of NBI-921352 for SCN8A developmental and epileptic encephalopathy. The payment consists of $6.75 million in cash and an $8.25 million equity investment at a premium price of $31.855 per share. This collaboration aims to enhance epilepsy treatment options for young patients.
Xenon Pharmaceuticals (Nasdaq:XENE) announced its key milestones for 2022, focusing on its lead product, XEN1101, which showed strong efficacy in a Phase 2b clinical trial for focal epilepsy. Plans include an FDA meeting in Q2 2022 and initiating a Phase 3 program later in the year. The company also aims to explore XEN1101 for major depressive disorder. Ongoing pediatric trials for XEN496 are expected to complete in early 2023. Collaborations with Neurocrine Biosciences and Pacira BioSciences are also highlighted, with potential milestone payments pending.
Xenon Pharmaceuticals (Nasdaq:XENE) announced promising results from the Phase 2b X-TOLE trial of XEN1101 for focal epilepsy, with statistically significant seizure reduction (p<0.001) across all dose groups. The 25 mg and 20 mg doses achieved median reductions of 52.8% and 46.4% in monthly seizures, respectively. The trial also demonstrated efficacy for difficult-to-treat patients. Xenon plans a Phase 3 trial and has long-term studies underway, reflecting strong potential for XEN1101 in market.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has announced its participation in the Annual Meeting of the American Epilepsy Society (AES 2021), highlighting significant updates on its neurology programs. CEO Ian Mortimer emphasized the advancement of XEN1101 and XEN496, with presentations scheduled to showcase Phase 2b clinical trial results and pre-clinical data on epilepsy treatments. A conference call is set for December 3, 2021, to discuss these results. The company aims to address unmet medical needs in epilepsy through innovative therapies.
FAQ
What is the current stock price of Xenon Pharmaceut (XENE)?
What is the market cap of Xenon Pharmaceut (XENE)?
